Articles by Rachel Lutz - Page 10

Latest Articles

FDA Approval Updates for Hemophilia Drugs
  |  Rachel Lutz
Over the past few months, the Food and Drug Administration (FDA) approved several drugs for the control and prevention of bleeding episodes in patients with hemophilia. Other drug classifications granted included Orphan Drug Status and Breakthrough Therapy designation.
Breaking Ground in Two Hemophilia Drug Construction Plants
  |  Rachel Lutz
Two new hemophilia drug plant construction plans were initiated over the summer by separate manufacturers, headlines said.
BAX 335 is Successful in Phase I and II Trials, Prevents Inhibitors
  |  Rachel Lutz
Seven patients have been treated successfully for hemophilia B and so far essentially none have developed inhibitors, according to the results of phase I and II trials of Baxalta drug BAX 335.
Analysis of Hemophilia Studies Fit Guidelines and Recommendations
  |  Rachel Lutz
An analysis of randomized controlled trials (RCTs) published by the Institute for Quality and Efficiency in Health Care (IQWiG) determined that prophylactic treatment for hemophilia A is superior to on demand treatment in some outcomes.
Smokers Often Show COPD Symptoms though Undiagnosed
  |  Rachel Lutz
Researchers assessed more than 2,700 current or former smokers in order to evaluate their respiratory symptoms using the COPD Assessment Test. Although many smokers did not meet the clinical definition of COPD, they nonetheless displayed several key symptoms.
Genetic Cause of Multiple Sclerosis Identified
  |  Rachel Lutz
Researchers have identified a specific genetic mutation that may increase the likelihood of developing a rapidly progressing form of multiple sclerosis.
Multiple Sclerosis Patients have Different Gut Microbiota
  |  Rachel Lutz
There are key differences in the gut microbial community composition in children with early-onset multiple sclerosis compared to healthy children without multiple sclerosis.
Diet and Gut Microbiome Influences Multiple Sclerosis Disease Activity
  |  Rachel Lutz
Researchers used pre-clinical models of MS, as well as samples from patients with MS, in order to demonstrate that diet and gut flora may influence the activity of astrocytes, the cells that control inflammation and neurodegeneration in the brain.
No Benefits from Umeclidinium for COPD Patients
  |  Rachel Lutz
There is no proof of the added benefit of using umeclidinium bromide for chronic obstructive pulmonary disease (COPD) symptom relief in patients.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$